China National Medicines Corporation Ltd. (SHA: 600511)

China National Medicines Corporation Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Operating Revenue	50,198	49,592	45,436	46,442	40,336	44,551
Other Revenue	113.94	103.99	62.95	26.26	43.04	93.71
Revenue	50,312	49,696	45,499	46,469	40,379	44,644
Revenue Growth (YoY)	5.63%	9.23%	-2.09%	15.08%	-9.56%	15.24%
Cost of Revenue	46,428	45,704	41,681	42,848	37,242	40,737
Gross Profit	3,884	3,992	3,817	3,621	3,136	3,908
Selling, General & Admin	1,343	1,430	1,392	1,355	1,404	1,473
Research & Development	65.66	71.2	67	55.75	51.87	44.93
Other Operating Expenses	128.89	109.69	46.91	120.86	105.54	104.36
Operating Expenses	1,545	1,618	1,498	1,566	1,571	1,639
Operating Income	2,339	2,374	2,319	2,055	1,566	2,269
Interest Expense	-21.35	-31.57	-26.88	-43.71	-56.81	-48.46
Interest & Investment Income	586.84	525.32	362.42	354.09	279.16	157.48
Currency Exchange Gain (Loss)	0.81	0.55	-1.65	2.71	1.57	-1.36
Other Non Operating Income (Expenses)	-11.01	-10.47	-43.29	-18	2.24	-6.95
EBT Excluding Unusual Items	2,894	2,858	2,609	2,350	1,792	2,370
Gain (Loss) on Sale of Investments	-23.91	10.82	-	-	-	-
Gain (Loss) on Sale of Assets	-0.36	0.08	1.68	-0.07	0.07	-0.53
Other Unusual Items	54.24	62.44	76.9	95.08	125.4	57.25
Pretax Income	2,924	2,931	2,688	2,445	1,917	2,427
Income Tax Expense	588.75	596.42	559.18	516.3	408.09	546.08
Earnings From Continuing Operations	2,335	2,334	2,129	1,929	1,509	1,880
Minority Interest in Earnings	-173.54	-188.47	-164.65	-174.42	-126.56	-276.58
Net Income	2,162	2,146	1,964	1,754	1,383	1,604
Net Income to Common	2,162	2,146	1,964	1,754	1,383	1,604
Net Income Growth	3.62%	9.26%	11.97%	26.86%	-13.79%	14.23%
Shares Outstanding (Basic)	754	754	755	755	754	762
Shares Outstanding (Diluted)	754	754	755	755	754	762
Shares Change (YoY)	-0.01%	-0.00%	-0.00%	0.00%	-0.98%	-0.62%
EPS (Basic)	2.87	2.84	2.60	2.32	1.83	2.10
EPS (Diluted)	2.87	2.84	2.60	2.32	1.83	2.10
EPS Growth	3.63%	9.27%	11.97%	26.86%	-12.94%	14.95%
Free Cash Flow	1,688	2,582	2,265	1,862	1,233	1,690
Free Cash Flow Per Share	2.24	3.42	3.00	2.47	1.63	2.22
Dividend Per Share	0.854	0.854	0.782	0.700	0.550	0.638
Dividend Growth	9.21%	9.21%	11.71%	27.27%	-13.79%	59.50%
Gross Margin	7.72%	8.03%	8.39%	7.79%	7.77%	8.75%
Operating Margin	4.65%	4.78%	5.10%	4.42%	3.88%	5.08%
Profit Margin	4.30%	4.32%	4.32%	3.77%	3.42%	3.59%
Free Cash Flow Margin	3.35%	5.19%	4.98%	4.01%	3.05%	3.79%
EBITDA	2,445	2,480	2,423	2,155	1,669	2,368
EBITDA Margin	4.86%	4.99%	5.32%	4.64%	4.13%	5.30%
D&A For EBITDA	105.6	106.15	103.86	100.1	103.46	98.42
EBIT	2,339	2,374	2,319	2,055	1,566	2,269
EBIT Margin	4.65%	4.78%	5.10%	4.42%	3.88%	5.08%
Effective Tax Rate	20.13%	20.35%	20.80%	21.12%	21.28%	22.50%
Revenue as Reported	50,312	49,696	45,499	46,469	40,379	44,644
Advertising Expenses	-	6.7	3.25	2.25	3.2	6.91

Source: S&P Capital IQ. Standard template. Financial Sources.